Tacrolimus 0,1% topical treatment outcome measurement in patients with morphea using mLoSSI tool

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Vavilov V.V.

MNPTsDK Departament zdravookhraneniia Moskvy;
Pervyĭ MGMU im. I.M. Sechenova

Tacrolimus 0,1% topical treatment outcome measurement in patients with morphea using mLoSSI tool

Authors:

Potekaev N.N., Vavilov V.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2013;11(6): 46‑51

Read: 4663 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Potekaev NN, Vavilov VV. Tacrolimus 0,1% topical treatment outcome measurement in patients with morphea using mLoSSI tool. Russian Journal of Clinical Dermatology and Venereology. 2013;11(6):46‑51. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Comparison of dermoscopic picture of the foci of localized scleroderma and tumor-associated localized scleroderma. Russian Journal of Clinical Dermatology and Venereology. 2025;(1):82-86

Evaluation of biochemical oncological markers and dermatoscopic picture in patients with tumor-associated localized scleroderma. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):153-159

Abstract:

Keywords:

morphea

calcineurin blockers

mLoSSI

severity index

Tacrolimus

Authors:

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Vavilov V.V.

MNPTsDK Departament zdravookhraneniia Moskvy;
Pervyĭ MGMU im. I.M. Sechenova

Close metadata

References:

Kroft E.B., Groeneveld T.J., Seyger M.M., de Jong E.M. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009; 10: 181-187.
Barbarino J.M., Staatz C.E., Venkataramanan R., Klein T.E., Altman R.B. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenetics Ggenomics 2013; 23: 10: 563-585.
Matsuda S., Shibasaki F., Takehana K., Mori H., Nishida E., Koyasu S. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep 20001; 5: 428-434.
Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 2: 240-246.
Potekaev N.N., Vavilov V.V., Cobolev V.V., Soboleva A.G., Zolotarenko A.D., Korsunskaya I.M., Bruskin S.A. Ekspressiya genov AR-1 transkriptsionnogo kompleksa v ochagakh porazheniya u bol'nykh ochagovoi sklerodermiei. Klin dermatol i venerol 2013; 2: 69-74.
Arkachaisri T., Vilaiyuk S., Li S., O'Neil K.M., Pope E., Higgins G.C. et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol 2009; 36: 2819-2829.
Arkachaisri T., Vilaiyuk S., Torok K.S., Medsger T.A. Jr. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) 2010; 49: 373-381.
Tuffanelli D.L., Winkelmann R.K. Systemic scleroderma. Arch Dermatol 1955; 84: 359-371.

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.